Research Topics
Species | Jacalyn RosenblattSummaryAffiliation: Harvard University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Immunomodulatory effects of vitamin D: implications for GVHDJ Rosenblatt
Division of Hematology Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
Bone Marrow Transplant 45:1463-8. 2010..These data suggest that exposure to vitamin D results in immature DC populations that bias toward tolerizing rather than stimulatory T-cell populations. Vitamin D may therefore have a role in the prevention of GVHD...- Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28Jacalyn Rosenblatt
Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
J Immunother 33:155-66. 2010..These findings indicate that stimulation with DC/tumor fusions provides a unique platform for subsequent expansion with anti-CD3/CD28 in adoptive T-cell therapy of cancer... - PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccineJacalyn Rosenblatt
Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
J Immunother 34:409-18. 2011..In summary, we demonstrate that PD-1 expression is increased in T cells of patients with active myeloma, and that CT-011 enhances activated T-cell responses after DC/tumor fusion stimulation... - Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cellsBaldev Vasir
Dana Farber Cancer Institute, Dana Farber Harvard Cancer Center, Brigham and Women s Hospital, Boston, MA 02115, USA
J Immunol 181:808-21. 2008..In contrast, exposure to TLR agonists, stimulatory cytokines, and anti-CD3/CD28 enhances vaccine efficacy by limiting the regulatory T cell response and promoting expansion of activated effector cells... - Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentationBaldev Vasir
Department of Medical Oncology and Dana Farber Harvard Cancer Center, Dana Farber Cancer Institute, Boston, MA 02115, USA
Br J Haematol 129:687-700. 2005..These findings demonstrate that tumour cell fusion induces DC maturation and the development of an activated phenotype necessary for their effectiveness as cancer vaccines... - The Medical Research Council Myeloma IX trial: the impact on treatment paradigmsPaul G Richardson
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Eur J Haematol 88:1-7. 2012.... - Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myelomaJacalyn Rosenblatt
Beth Israel Deaconess Medical Center, Boston, MA, USA
Blood 117:393-402. 2011..Vaccination with DC/multiple myeloma fusions was feasible and well tolerated and resulted in antitumor immune responses and disease stabilization in a majority of patients... - MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cellsLi Yin
Dana Farber Cancer Institute, Boston, MA, USA
Blood 117:4863-70. 2011..These findings indicate that MUC1-C function is of importance to AML cell self-renewal and that inhibition of MUC1-C represents a potential therapeutic approach to induce terminal differentiation of AML cells... - Dendritic cell fusion vaccines for cancer immunotherapyJacalyn Rosenblatt
Hematologic Malignancy Bone Marrow Transplant Program, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, KS 121, Boston, MA 02215, USA
Expert Opin Biol Ther 5:703-15. 2005..Preliminary results demonstrate that generation of a vaccine is feasible and that vaccination is associated with minimal toxicity. Immunological and clinical responses have been found in a subset of patients... - MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cellsTakeshi Kawano
Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
Cancer Res 67:11576-84. 2007..These findings indicate that MUC1 stabilizes Bcr-Abl and contributes to the pathogenesis of CML cells by promoting self renewal and inhibiting differentiation and apoptosis... - Cellular immunotherapy for multiple myelomaJacalyn Rosenblatt
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Best Pract Res Clin Haematol 21:559-77. 2008.... - Can leukemia-derived dendritic cells generate antileukemia immunity?Jacalyn Rosenblatt
Beth Israel Deaconess Medical Center, Hematologic Malignancy Bone Marrow Transplant Program, 330 Brookline Avenue, KS 121, Boston, MA 02215, USA
Expert Rev Vaccines 5:467-72. 2006..However, the efficacy of this approach may be limited by intrinsic abnormalities in the malignant clone that prevent differentiation towards a normal DC phenotype... - Management of relapsed and relapsed/refractory multiple myelomaJacob P Laubach
Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
J Natl Compr Canc Netw 9:1209-16. 2011..Moreover, the development of new drug classes based on preclinical rationale and the introduction of next-generation agents is likely to further expand treatment options and improve outcomes for relapsed MM... - Immunotherapy for renal cell carcinomaJacalyn Rosenblatt
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
Hematol Oncol Clin North Am 25:793-812. 2011..This review describes how improvements in patient selection, combination therapy, and investigational agents might expand and better define the role of immunotherapy in metastatic RCC...